Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Wiersma

Showing results (21-30 of 31) with videos related to

Pageof 4
Sort By:
Medical Dosimetry : Official Journal of the American Association of Medical Dosimetrists|August 24, 2018
A robust volumetric arc therapy planning approach for breast cancer involving the axillary nodesGijs J van der Veen, Tomas Janssen, Amber Duijn, et al.
Haematologica|February 14, 2007
Low frequency maintenance therapy with imiglucerase in adult type I Gaucher disease: a prospective randomized controlled trialMaaike de Fost, Johannes M F G Aerts, Johanna E M Groener, et al.
Blood Cells, Molecules & Diseases|January 16, 2010
Spontaneous regression of disease manifestations can occur in type 1 Gaucher disease; results of a retrospective cohort studyJooske M F Boomsma, Laura van Dussen, Maaike G Wiersma, et al.
Journal of Inherited Metabolic Disease|March 4, 2009
Different dose-dependent correction of MIP-1beta and chitotriosidase during initial enzyme replacement therapyM J van Breemen, M de Fost, M Maas, et al.
Lung Cancer (Amsterdam, Netherlands)|January 30, 2013
Concurrent chemoradiotherapy for large-volume locally-advanced non-small cell lung cancerTerry G Wiersma, Max Dahele, Wilko F A R Verbakel, et al.
Blood|March 11, 2006
Superior effects of high-dose enzyme replacement therapy in type 1 Gaucher disease on bone marrow involvement and chitotriosidase levels: a 2-center retrospective analysisMaaike de Fost, Carla E M Hollak, Johanna E M Groener, et al.
The British Journal of Surgery|June 22, 2021
Toward omitting sentinel lymph node biopsy after neoadjuvant chemotherapy in patients with clinically node-negative breast cancerM E M van der Noordaa, F H van Duijnhoven, F N E Cuijpers, et al.
Cancer Treatment and Research Communications|July 10, 2026
Local ablative treatment and continuation of systemic therapy for oligoprogressive metastatic breast cancer: a retrospective cohort studyCornelia A M Almekinders, Tess I M Snellen, Annemiek van Ommen-Nijhof, et al.
European Journal of Cancer (Oxford, England : 1990)|November 3, 2024
Intensified alkylating chemotherapy for patients with oligometastatic breast cancer harboring homologous recombination deficiency: Primary outcomes from the randomized phase III OLIGO studyA van Ommen-Nijhof, T G Steenbruggen, T G Wiersma, et al.
Nature Medicine|May 16, 2019
Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trialLeonie Voorwerk, Maarten Slagter, Hugo M Horlings, et al.
Pageof 4

Showing results (21-30 of 31) with videos related to

Sort By:
Pageof 4
Medical Dosimetry : Official Journal of the American Association of Medical Dosimetrists|August 24, 2018
A robust volumetric arc therapy planning approach for breast cancer involving the axillary nodesGijs J van der Veen, Tomas Janssen, Amber Duijn, et al.
Haematologica|February 14, 2007
Low frequency maintenance therapy with imiglucerase in adult type I Gaucher disease: a prospective randomized controlled trialMaaike de Fost, Johannes M F G Aerts, Johanna E M Groener, et al.
Blood Cells, Molecules & Diseases|January 16, 2010
Spontaneous regression of disease manifestations can occur in type 1 Gaucher disease; results of a retrospective cohort studyJooske M F Boomsma, Laura van Dussen, Maaike G Wiersma, et al.
Journal of Inherited Metabolic Disease|March 4, 2009
Different dose-dependent correction of MIP-1beta and chitotriosidase during initial enzyme replacement therapyM J van Breemen, M de Fost, M Maas, et al.
Lung Cancer (Amsterdam, Netherlands)|January 30, 2013
Concurrent chemoradiotherapy for large-volume locally-advanced non-small cell lung cancerTerry G Wiersma, Max Dahele, Wilko F A R Verbakel, et al.
Blood|March 11, 2006
Superior effects of high-dose enzyme replacement therapy in type 1 Gaucher disease on bone marrow involvement and chitotriosidase levels: a 2-center retrospective analysisMaaike de Fost, Carla E M Hollak, Johanna E M Groener, et al.
The British Journal of Surgery|June 22, 2021
Toward omitting sentinel lymph node biopsy after neoadjuvant chemotherapy in patients with clinically node-negative breast cancerM E M van der Noordaa, F H van Duijnhoven, F N E Cuijpers, et al.
Cancer Treatment and Research Communications|July 10, 2026
Local ablative treatment and continuation of systemic therapy for oligoprogressive metastatic breast cancer: a retrospective cohort studyCornelia A M Almekinders, Tess I M Snellen, Annemiek van Ommen-Nijhof, et al.
European Journal of Cancer (Oxford, England : 1990)|November 3, 2024
Intensified alkylating chemotherapy for patients with oligometastatic breast cancer harboring homologous recombination deficiency: Primary outcomes from the randomized phase III OLIGO studyA van Ommen-Nijhof, T G Steenbruggen, T G Wiersma, et al.
Nature Medicine|May 16, 2019
Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trialLeonie Voorwerk, Maarten Slagter, Hugo M Horlings, et al.
Pageof 4